Imugene doses first Australian subject in trial of B-cell lymphoma drug candidate
Australian immuno-oncology company Imugene has dosed the first Australian subject in a Phase Ib trial of its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel). The trial is evaluating azer-cel’s ability to treat relapsed or refractory …